MetaCap

PolyPid Ltd. (PYPD)

NASDAQ: PYPDHealth CareMedical/Dental InstrumentsUSD

6.12-0.43 (-6.56%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PYPD stock chart

Technical analysis

Key statistics

All statistics
Market cap
$129.29M
EPS (TTM)
-$1.31
52-week range
3.60 – 7.25
Day range
6.09 – 6.76
Volume / Avg
448.95K / 148.00K
Beta
—

52-week range

$3.60$7.25

PYPD stock today

On Nov 20, PYPD ended the session at $6.12, shedding $0.43 (6.56%), versus the S&P 500's 3.70% decline. Volume was 3.0x the average at 448.95K shares, a sign of unusually heavy trading. Shares are 15.6% below their 52-week high of $7.25, set on Nov 19, 2026 and 70.0% above the 52-week low of $3.60, in the middle of the past year's range.

PYPD is up 41.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 70.0%. PolyPid has posted a net loss over the last twelve months (EPS of -$1.31), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About PolyPid

Company profile

PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer.

Industry
Medical/Dental Instruments
CEO
Ms. Dikla Czaczkes Akselbrad
Headquarters
Petah Tikva
Employees
69
IPO year
2020

Financial highlights

Full financials

PolyPid reported a net loss of $34.2 million, compared with a loss of $29.0 million a year earlier. Diluted earnings per share came in at $2.09, down from $4.91.

PolyPid annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-34.17M$-29.02M$-23.86M$-39.56M$-42.60M
EPS (diluted)$2.09$4.91$16.93$61.09$68.27

Analyst forecast

Forecast

Consensus (5 analysts)

strong_buy

Avg. price target

$11.50+87.91%

  • Strong buy 1
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.50High $14.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 11, 2026
EPS actual vs est.
$-0.24 vs $0.46
Surprise
-152.17%

PYPD news

All PYPD news

PolyPid peers

Health Care sector
PYPD peer companies
CompanyPrice% ChgMarket capCompare
STIMNeuronetics Inc.1.25+0.81%$120.60Mvs PYPD
KRMDKORU Medical Systems Inc.3.19-7.27%$138.37Mvs PYPD
LUNGPulmonx Corporation2.57-6.20%$111.93Mvs PYPD
APYXApyx Medical Corporation2.40+0.42%$101.10Mvs PYPD
NYXHNyxoah SA0.805-7.01%$81.98Mvs PYPD
ANIKAnika Therapeutics Inc.13.23-0.38%$177.22Mvs PYPD
SKINSkinHealth Systems Inc. Class A11.77-3.13%$76.68Mvs PYPD
LUCDLucid Diagnostics Inc.0.3727-3.52%$72.57Mvs PYPD

Indexes, lists and sector

PolyPid stock FAQ

What is PolyPid's stock price today?

PYPD last traded at $6.12 as of Nov 20, 4:00 PM EST, down 6.56% on the day. Prices are delayed at least 15 minutes.

Does PolyPid pay a dividend?

No. PolyPid does not currently pay a regular cash dividend.

Who is PolyPid's CEO?

Ms. Dikla Czaczkes Akselbrad is the chief executive officer of PolyPid Ltd., which has about 69 employees.

Has PYPD ever split its stock?

Yes. The most recent PYPD stock split was a 1-for-30 split on Sep 21, 2023.

What is the PYPD 52-week high?

The 52-week high for PYPD is $7.25 and the 52-week low is $3.60. The stock is currently 15.6% below its high.

Compare PYPD